Nkarta Inc (NKTX) Stock Analysis

Nkarta Inc (NKTX) is a publicly traded company in the HEALTHCARE sector. It trades at $3.14, carries a market capitalization of $224.65M. This page summarizes the public market data, fundamentals, and frequently asked questions for NKTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Nkarta Inc currently has a Bearish sentiment score of -0.20.

About Nkarta Inc

Nkarta, Inc. is a clinical-stage biopharmaceutical company located in South San Francisco, California, dedicated to pioneering advanced cell therapies for the treatment of cancer. Utilizing its proprietary technology platform, Nkarta is developing innovative therapies that leverage the immune system to effectively target and eradicate cancer cells. The company boasts a strong pipeline of product candidates in multiple clinical development phases, positioning itself as a key player in addressi...

GNG Research Analysis

GNG Research scores Nkarta Inc (NKTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NKTX.

Frequently Asked Questions

Does NKTX pay dividends?

Nkarta Inc (NKTX) does not currently pay a regular dividend.

What is NKTX's market cap?

Nkarta Inc (NKTX) has a market capitalization of $224.65M with a current stock price of $3.14.